LEXARIA BIOSCIENCE C

LEXX
Delayed Quote. Delayed  - 01/19 03:59:58 pm
4.34USD -5.24%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: August 2015 2016 2017 2018 2019 2020
Net sales1 0,010,040,060,430,220,38
EBITDA --1,24-1,83-6,61-3,93-3,75
Operating profit (EBIT)1 -1,91-1,24-1,83-6,61-3,99-3,86
Operating Margin -12 993%-3 053%-2 878%-1 526%-1 793%-1 004%
Pre-Tax Profit (EBT)1 -1,98-1,28-1,93-6,61-4,16-4,08
Net income1 -1,77-1,21-1,87-6,60-4,10-3,93
Net margin -12 043%-2 983%-2 937%-1 523%-1 842%-1 023%
EPS2 -1,34-0,83-0,95-2,79-1,58-1,42
Dividend per Share ------
Last update 11/28/201611/14/201811/14/201811/14/201910/14/202010/14/2020
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: August 2015 2016 2017 2018 2019 2020
Net Debt1 ------
Net Cash position1 0,26-2,531,741,351,16
Leverage (Debt / EBITDA) --1,38x0,26x0,34x0,31x
Free Cash Flow1 0,50-0,19-0,73-0,10-2,07-1,03
ROE (Net Profit / Equities) -167%-343%-135%-256%-170%-164%
Shareholders' equity1 1,060,351,382,572,402,39
ROA (Net Profit / Asset) -71,3%-122%-66,8%-156%-97,7%-87,7%
Assets1 2,481,002,804,224,204,48
Book Value Per Share2 0,53-1,330,950,910,84
Cash Flow per Share2 0,18-1,120,690,490,43
Capex -0,00--0,65-
Capex / Sales -7,60%--290%-
Last update 11/28/201611/14/201811/14/201811/14/201910/14/202010/14/2020
1 USD in Million
2 USD
Balance Sheet Analysis
Price Earning Ratio
EPS & Dividend